Uni Prot Comments Displayer
Protein Atlas Displayer
Gene Expression Atlas Tissues Displayer
Gene Expression Atlas Diseases Displayer
Publication Counts Displayer
Curated Proteins Displayer
Function
Gene Ontology Displayer
65 Pathways
- Disease,
- Pathways in cancer,
- Signaling by FGFR4,
- Signaling by NTRK1 (TRKA),
- Negative regulation of FGFR4 signaling,
- Oncogenic MAPK signaling,
- Hepatitis C,
- Thyroid cancer,
- Negative regulation of FGFR1 signaling,
- Focal adhesion,
- Regulation of actin cytoskeleton,
- Signal Transduction,
- Chemokine signaling pathway,
- Signaling by NTRKs,
- Signaling by moderate kinase activity BRAF mutants,
- MAPK signaling pathway,
- Negative regulation of FGFR2 signaling,
- Negative feedback regulation of MAPK pathway,
- Pancreatic cancer,
- Chronic myeloid leukemia,
- Non-small cell lung cancer,
- Long-term depression,
- RAF activation,
- Vascular smooth muscle contraction,
- Melanoma,
- Renal cell carcinoma,
- Acute myeloid leukemia,
- Negative regulation of FGFR3 signaling,
- mTOR signaling pathway,
- MAP2K and MAPK activation,
- Prostate cancer,
- Diseases of signal transduction by growth factor receptors and second messengers,
- Immune System,
- Signaling by RAS mutants,
- Signalling to p38 via RIT and RIN,
- Colorectal cancer,
- Neurotrophin signaling pathway,
- Cytokine Signaling in Immune system,
- Frs2-mediated activation,
- Signaling by FGFR1,
- Signaling by Receptor Tyrosine Kinases,
- Progesterone-mediated oocyte maturation,
- ARMS-mediated activation,
- FLT3 Signaling,
- ErbB signaling pathway,
- Endometrial cancer,
- Insulin signaling pathway,
- Signaling by FGFR,
- Signaling by high-kinase activity BRAF mutants,
- MAPK family signaling cascades,
- Natural killer cell mediated cytotoxicity,
- MAPK1/MAPK3 signaling,
- Signaling by BRAF and RAF fusions,
- Bladder cancer,
- Glioma,
- Prolonged ERK activation events,
- Negative regulation of MAPK pathway,
- Long-term potentiation,
- Paradoxical activation of RAF signaling by kinase inactive BRAF,
- RAF/MAP kinase cascade,
- Signaling by FGFR3,
- Signaling downstream of RAS mutants,
- Signalling to ERKs,
- Spry regulation of FGF signaling,
- Signaling by FGFR2
Gene --> GO terms.
Gene -> HPO annotation (Human Phenotype Ontology)
Mouse Gene --> Allele [Phenotype]
Genomics
J Browse Displayer
Gene Structure Displayer
Overlapping Features Displayer
Mouse Alleles Displayer
Gene --> Chromosomal location.
Gene --> GO terms.
Gene --> Overlapping genes.
Disease
Gene (Hum OR Rat) --> Mouse Allele (Phenotype)
Gene --> Alleles and Disease (clinVar data)
Gene -> HPO annotation (Human Phenotype Ontology)
Mouse Gene --> Allele [Phenotype]
Other
65 Pathways
- Disease,
- Pathways in cancer,
- Signaling by FGFR4,
- Signaling by NTRK1 (TRKA),
- Negative regulation of FGFR4 signaling,
- Oncogenic MAPK signaling,
- Hepatitis C,
- Thyroid cancer,
- Negative regulation of FGFR1 signaling,
- Focal adhesion,
- Regulation of actin cytoskeleton,
- Signal Transduction,
- Chemokine signaling pathway,
- Signaling by NTRKs,
- Signaling by moderate kinase activity BRAF mutants,
- MAPK signaling pathway,
- Negative regulation of FGFR2 signaling,
- Negative feedback regulation of MAPK pathway,
- Pancreatic cancer,
- Chronic myeloid leukemia,
- Non-small cell lung cancer,
- Long-term depression,
- RAF activation,
- Vascular smooth muscle contraction,
- Melanoma,
- Renal cell carcinoma,
- Acute myeloid leukemia,
- Negative regulation of FGFR3 signaling,
- mTOR signaling pathway,
- MAP2K and MAPK activation,
- Prostate cancer,
- Diseases of signal transduction by growth factor receptors and second messengers,
- Immune System,
- Signaling by RAS mutants,
- Signalling to p38 via RIT and RIN,
- Colorectal cancer,
- Neurotrophin signaling pathway,
- Cytokine Signaling in Immune system,
- Frs2-mediated activation,
- Signaling by FGFR1,
- Signaling by Receptor Tyrosine Kinases,
- Progesterone-mediated oocyte maturation,
- ARMS-mediated activation,
- FLT3 Signaling,
- ErbB signaling pathway,
- Endometrial cancer,
- Insulin signaling pathway,
- Signaling by FGFR,
- Signaling by high-kinase activity BRAF mutants,
- MAPK family signaling cascades,
- Natural killer cell mediated cytotoxicity,
- MAPK1/MAPK3 signaling,
- Signaling by BRAF and RAF fusions,
- Bladder cancer,
- Glioma,
- Prolonged ERK activation events,
- Negative regulation of MAPK pathway,
- Long-term potentiation,
- Paradoxical activation of RAF signaling by kinase inactive BRAF,
- RAF/MAP kinase cascade,
- Signaling by FGFR3,
- Signaling downstream of RAS mutants,
- Signalling to ERKs,
- Spry regulation of FGF signaling,
- Signaling by FGFR2
